ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Pleven, Bulgaria, 5800
- Department of Chemotherapy, University General Hospital for Active Treatment "Georgi Stranski"
-
Plovdiv, Bulgaria, 4004
- 1st Internal Department District Dispensary for Cancer Diseases with Inpatient Hospital
-
Sofia, Bulgaria, 1431
- Multifile Hospital "Aleksandrovska", Urology Clinic, Department of Oncourology
-
Sofia, Bulgaria, 1527
- Oncology Clinic, University General Hospital for Active Treatment "Tzaritza Yoanna"
-
Varna, Bulgaria, 9002
- Urology Clinic, General Hospital for Active Treatment "St. Anna"
-
Veliko Tarnovo, Bulgaria, 5000
- Department of Chemotherapy, Inter-district Dispensary for Cancer Diseases with Inpatient Hospital
-
-
-
-
-
Bucharest, Romania, 022328
- Fundeni Clinical Institute - Urology Department
-
Bucharest, Romania, 041345
- Dinu Uromedica
-
Bucharest, Romania, 050659
- "Prof. Dr. Th. Burghele" Clinical Hospital, Urology Clinic
-
Cluj Napoca, Romania, 400015
- "I. Chiricuta" Institute of Oncology
-
Cluj Napoca, Romania, 400016
- E-URO Medical Center
-
Constanta, Romania, 900635
- Provita Center SRL
-
Sibiu, Romania, 550245
- Sibiu Clinical Country Hospital - Urology Clinic
-
Timisoara, Romania, 300239
- Oncomed SRL
-
-
-
-
-
Arkhangelsk, Russian Federation
- Arkhangelsk Regional Oncology Center
-
Chelyabinsk, Russian Federation, 454087
- Chelyabinsk Regional Oncology Center
-
Kazan, Russian Federation, 420029
- Republican Clinical Oncology Center
-
Kazan, Russian Federation, 420111
- Kazan City Oncology Center
-
Moscow, Russian Federation, 115478
- Russian Oncological Research Center n.a. N.N. Blokhin
-
Moscow, Russian Federation, 105425
- Research Institute of Urology
-
Moscow, Russian Federation, 117997
- Russian Research Center of Radiology
-
Obninsk, Russian Federation, 249036
- Medical Radiology Research Center
-
Orenburg, Russian Federation, 460021
- Orenburg Regional Clinical Oncology Center
-
St. Petersburg, Russian Federation, 191104
- Leningrad Regional Oncological Center
-
St. Petersburg, Russian Federation, 193312
- Municipal Aleksandrovskaya Hospital
-
St. Petersburg, Russian Federation, 194354
- Municipal Multi-Speciality Hospital #2
-
St. Petersburg, Russian Federation, 196247
- Municipal Hospital #26
-
St. Petersburg, Russian Federation, 197022
- Municipal Clinical Oncology Center
-
St. Petersburg, Russian Federation, 197758
- Central Research Institute of Roentgenology and Radiology
-
St. Petersburg, Russian Federation, 197758
- Research Institute of Oncology n.a. Professor N.N. Petrov
-
St. Petersburg, Russian Federation, 198205
- Municipal Hospital #15
-
Stavropol, Russian Federation, 355047
- Stavropol Territorial Clinical Oncology Center
-
Yaroslavl, Russian Federation, 150054
- Regional Clinical Oncology Hospital
-
-
-
-
-
Cherkassy, Ukraine, 18009
- Cherkassy Regional Oncology Center
-
Chernigov, Ukraine, 14029
- Chernigov Regional Oncology Center
-
Dnepropetrovsk, Ukraine, 49005
- Urology Department, Dnepropetrovsk State Medical Academy
-
Dnepropetrovsk, Ukraine, 49102
- City General Hospital #4
-
Donetsk, Ukraine, 83092
- Donetsk Regional Antitumor Center
-
Ivano-Frankovsk, Ukraine, 76000
- Ivano-Frankovsk Regional Oncology Center
-
Kharkiv, Ukraine, 61037
- Kharkiv Regional Urology and Nephrology Center
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Department of Plastic and Supportive Urology
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Urology Department
-
Lvov, Ukraine, 79031
- State Regional Diagnostics and Treatment Oncology Center
-
Uzhorod, Ukraine, 88014
- Regional Oncology Center
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital, Cambridge Clinical Trials Centre
-
Derby, United Kingdom, DE1 2QY
- Derby Hospital NHS Trust
-
Glasgow, United Kingdom, G12 0YN
- The Beatson West of Scotland Cancer Centre
-
Leeds, United Kingdom, LS9 7TF
- St. James's Institute of Oncology
-
London, United Kingdom, SW6 6JJ
- The Royal Marsden NHS Trust
-
Manchester, United Kingdom, M20 4BX
- The Christie Hospital NHS Trust
-
Swansea, United Kingdom, SA2 8QA
- South Wales Cancer Institute, Singleton Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed RCC (clear cell and papillary types)
- Metastatic or inoperable locally advanced RCC
- Eligible for therapy with IFN-alpha.
- Measurable disease defined by at least 1 measurable lesion on CT scan (lesion diameter greater than or equal to 2.0 cm by a standard CT scanner or greater than or equal to 1.0 cm by a spiral CT scanner)
- Favorable or moderate risk group prognosis by MSKCC (Motzer) criteria (score 0-2)
- Karnofsky performance status greater than or equal to 70
- Age greater than or equal to 18
- Life expectancy greater than 3 months
Baseline blood counts:
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
- Platelets greater than or equal to 100 x 10^9/L
- Haemoglobin greater than or equal to 100 g/L
Baseline blood chemistry levels:
- Creatinine less than or equal to 1.5 x upper limit of normal (ULN)
- Bilirubin less than or equal to 2 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN. AST and ALT allowed less than or equal to 5 x ULN for patients with liver metastases.
- If fertile, patient will use effective method of contraception throughout the study
- Willing and able to comply with the treatment and follow-up visits and examinations
- Capable of understanding the parameters in the protocol and able to sign a written consent form
Exclusion Criteria:
- Pregnant or breastfeeding women
- Serious uncontrolled medical disorder or active infection ongoing or resolved within 2 weeks before first dose of study drug and that the investigator believes would impair the patient's ability to receive study drug
- History of malignancy within 5 years or concurrent malignancy, except successfully treated non-melanoma skin cancer, cervical cancer in situ, ductal carcinoma in situ or lobular carcinoma in situ of breast may be included
- History and/or signs of parenchymal brain metastases
- Significant cardiac disease including: history (within 6 months) or current unstable angina pectoris, congestive heart failure (NYHA stage III-IV), myocardial infarction within 12 months, or uncontrolled arterial hypertension.
- History of stroke within 5 years and/or transient ischemic attack within 6 months.
- Acute illness or evidence of infection, including unexplained fever (>100.5ºF or 38.1ºC) within 2 weeks before start of treatment
- Treatment with biological response modifiers within 3 weeks prior to the start of treatment and up to the End-of-Study visit
- Treatment with beta-blockers, including topical therapy for glaucoma, within 5 days before start of treatment and during the 4-day ABR-217620/naptumomab estafenatox treatment
- Treatment with systemic corticosteroids within 2 weeks before start of treatment or likely need for such treatment during the study
- Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis
- Known positive serology for HIV
- Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known virus carrying; patients who recovered from Hepatitis A are allowed
- Treatment with anticoagulants within 2 weeks before start of treatment, except when used to maintain the patency of a central or peripheral venous line
- Radiotherapy less than 4 weeks before start of treatment
- Major surgery or tumor embolization less than 4 weeks before start of treatment
- Previous exposure to murine monoclonal antibodies or known hypersensitivity to murine proteins
- Currently on renal dialysis treatment
- Known allergy or hypersensitivity to aminoglycosides and kanamycin
- Previous systemic anti-tumor therapy for RCC (including immunotherapy with IFN-alpha or IL-2 or any chemotherapy) except sunitinib or other oral antiangiogenic therapy
- Participation in any study with investigational drugs for RCC within 6 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Other Names:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Other Names:
|
|
Experimental: Safety group
6-12 patients
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Other Names:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Other Names:
|
|
Other: 2
Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
|
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to death
Time Frame: every 12 weeks, including after a maximum of 18 months of study treatment
|
every 12 weeks, including after a maximum of 18 months of study treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival time
Time Frame: every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
|
Objective tumor response rate
Time Frame: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Best overall response
Time Frame: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Duration of response
Time Frame: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Changes in sum of target lesions
Time Frame: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Immunological response in patients on combined treatment of ABR-217620/naptumomab estafenatox and IFN-alpha
Time Frame: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Vital signs
Time Frame: every visit through Week 25, plus Week 73
|
every visit through Week 25, plus Week 73
|
|
Physical measurements
Time Frame: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Adverse events
Time Frame: every visit through Week 73
|
every visit through Week 73
|
|
Laboratory safety assessments
Time Frame: Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
|
Pharmacokinetic parameters of ABR-217620/naptumomab estafenatox
Time Frame: Weeks 1, 9, and 17
|
Weeks 1, 9, and 17
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Thore Nederman, PhD, Active Biotech AB
Publications and helpful links
General Publications
- Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle O, Eisen T. A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNalpha versus IFNalpha in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clin Cancer Res. 2016 Jul 1;22(13):3172-81. doi: 10.1158/1078-0432.CCR-15-0580. Epub 2016 Feb 5.
- Eisen T, Hedlund G, Forsberg G, Nordle Ö, Hawkins R. Baseline biomarker trend analysis of a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α vs IFN-α in advanced renal cell carcinoma. European Cancer Congress (ECCO) 2013; Abstract ID: 2710.
- Elkord E, Burt DJ, Sundstedt A, Nordle O, Hedlund G, Hawkins RE. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget. 2015 Feb 28;6(6):4428-39. doi: 10.18632/oncotarget.2922.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies, Monoclonal
- Immunoconjugates
Other Study ID Numbers
Other Study ID Numbers
- 06762004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.